研報掘金丨中信證券:予復星醫藥“買入”評級 利潤率有望逐步改善
中信證券發表復星醫藥(2196.HK)最新研報顯示,隨着新冠相關業務負面影響出清,復星醫藥經營拐點明確,單季度盈利已回到疫情前水準,隨着業務聚焦,利潤率有望逐步改善。參考可比公司估值,給予復星醫藥2024年27倍市盈率,對應目標價32港元,維持“買入”的投資評級。報吿表示,2024年第一季度復星醫藥的歸母淨利潤和扣非淨利潤均已經回升到疫情前2019年水準,且隨着公司業務聚焦,逐步剝離非核心資產,利潤率有望迎來上行。另一方面,隨着6月份,復星醫藥宣佈擬私有化旗下子公司復宏漢霖(02696.HK),進一步聚焦製藥業務及創新藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.